StockNews.com upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP – Free Report) from a hold rating to a buy rating in a research note issued to investors on Tuesday.
Separately, HC Wainwright restated a neutral rating on shares of Oramed Pharmaceuticals in a research note on Monday, May 20th.
Get Our Latest Stock Report on ORMP
Oramed Pharmaceuticals Stock Performance
Institutional Trading of Oramed Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its stake in shares of Oramed Pharmaceuticals by 52.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after acquiring an additional 10,774 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Oramed Pharmaceuticals in the 2nd quarter valued at about $40,000. Assenagon Asset Management S.A. bought a new stake in shares of Oramed Pharmaceuticals in the 1st quarter valued at about $54,000. Virtu Financial LLC bought a new stake in shares of Oramed Pharmaceuticals in the 1st quarter valued at about $68,000. Finally, Renaissance Technologies LLC increased its stake in shares of Oramed Pharmaceuticals by 89.0% in the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after acquiring an additional 108,700 shares during the last quarter. 12.73% of the stock is owned by institutional investors.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Recommended Stories
- Five stocks we like better than Oramed Pharmaceuticals
- Market Cap Calculator: How to Calculate Market Cap
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- Consumer Discretionary Stocks Explained
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.